Mounjaro and Gallbladder Problems: Gallstones, Risk & Warning Signs (2026)

Gallbladder problems are a recognized adverse effect tied to tirzepatide. Mounjaro is tirzepatide — a dual GIP and GLP-1 receptor agonist, the same molecule sold for weight management as Zepbound — and the Zepbound prescribing information specifically notes cholelithiasis (gallstones) among adverse reactions in the obesity trials.^[1] A meta-analysis of randomized trials found GLP-1-based drugs are associated with a modest but real increase in gallbladder and biliary disease, more so at higher doses and with greater weight loss.^[3] The risk comes from two directions at once: incretin drugs can slow gallbladder emptying and motility, which lets bile stagnate and stones form; and the rapid or substantial weight loss tirzepatide produces is itself a long-established, independent risk factor for gallstones — and because tirzepatide drives large weight loss, that contribution is amplified.^[3][4] This guide explains why gallbladder trouble happens on Mounjaro, the warning signs of a gallbladder attack you should never ignore, and the practical, prescriber-directed steps that lower the risk. See our Mounjaro drug page and our companion guide on gallbladder problems on semaglutide. This is general educational information, not medical advice — your prescriber manages your care.

Can Mounjaro cause gallbladder problems?

Yes — gallbladder disease is a recognized adverse effect associated with tirzepatide. Tirzepatide is a dual GIP/GLP-1 receptor agonist, and the Zepbound (tirzepatide for chronic weight management) prescribing information specifically lists cholelithiasis (gallstones) among the adverse reactions reported in the obesity trials.^[1] Because Mounjaro and Zepbound are the same molecule at the same dose strengths — Mounjaro is branded for type 2 diabetes, Zepbound for weight management — the same gallbladder considerations apply to both, and side effects in general tend to be more common at higher doses and with greater weight loss.^[2]

How big is the risk? A systematic review and meta-analysis of randomized clinical trials published in JAMA Internal Medicine in 2022 found that GLP-1 receptor agonists were associated with a modest but statistically significant increase in gallbladder and biliary diseases — including cholelithiasis and cholecystitis — and that the excess risk was higher with higher doses, longer treatment, and use for weight loss rather than diabetes.^[3] Tirzepatide shares the GLP-1 arm of that mechanism and produces some of the largest average weight loss of any approved agent, which is precisely the setting where the meta-analysis found the most gallbladder risk. In plain terms: most people on Mounjaro will not develop gallbladder problems, but the risk is real, it is not zero, and it rises with the factors that also drive bigger weight loss. The MedlinePlus consumer summary for tirzepatide likewise reminds patients to contact their prescriber about severe abdominal symptoms.^[5]

Why it happens — two mechanisms at once

The gallbladder stores and concentrates bile and squeezes it into the gut to help digest fat. Gallstones form when bile stagnates or becomes over-concentrated with cholesterol. On Mounjaro, two separate pathways push in that direction at the same time:

• The drug can slow gallbladder emptying and motility. Incretin-based drugs — including the GLP-1 component of tirzepatide — slow gastric emptying and can also reduce gallbladder contraction and emptying. When the gallbladder empties less completely, bile sits longer and becomes more concentrated — conditions that favor sludge and stone formation. This is a drug-driven contribution that is independent of how much weight you lose.^[3]
• Rapid or substantial weight loss is itself a gallstone risk factor — and tirzepatide drives large loss. Long before incretin drugs existed, fast or large weight loss was a well-established, independent cause of gallstones — the faster and greater the loss, the higher the risk. During rapid weight loss the liver secretes more cholesterol into bile and the gallbladder empties less often, both of which promote stones. Because tirzepatide produces some of the largest weight loss of any approved medication, this driver is amplified. A classic clinical analysis used exactly this gallstone risk to define a medically safe rate of weight loss.^[4]

That dual mechanism is why the meta-analysis found the highest gallbladder risk in the weight-loss setting and at higher doses: those are precisely the situations that combine the drug's effect on the gallbladder with the largest, fastest weight loss.^[3] So the risk on Mounjaro comes from both the drug and the weight loss it causes — which is also why the strategies that lower the risk focus on moderating the pace of weight loss, not just the drug.

Warning signs of a gallbladder attack

A gallstone can sit silently for years, but if it blocks a bile duct or the gallbladder becomes inflamed (cholecystitis), it can cause a gallbladder attack — and some presentations are medical emergencies. Know the warning signs so you can act fast.

How to lower your gallbladder risk on Mounjaro

Because the risk comes from both the drug and the pace of weight loss, the most useful steps target the modifiable side — the speed of weight loss, hydration, and diet — while keeping your prescriber in the loop. The following are general, commonly-discussed strategies, and all of them are prescriber-directed. Do not change your Mounjaro dose, start a supplement, or adjust other medications without talking to your clinician.

• Avoid crash-dieting — lose weight at a moderate pace. Because rapid, large weight loss is itself a gallstone driver, and tirzepatide already produces sizable loss, letting weight come off gradually and steadily rather than as fast as possible meaningfully lowers the risk. The classic clinical work on this defined a medically safe rate of weight loss specifically to limit gallstone formation.^[4]
• Stay well hydrated. Adequate fluids support healthy bile flow, and hydration also guards against the dehydration that can accompany the gastrointestinal side effects common with tirzepatide. Keep fluids steady through the day, with extra attention during any nausea, vomiting, or diarrhea.^[5]
• Eat regular, balanced meals — including some healthy fat. The gallbladder contracts to release bile when you eat fat; meals with almost no fat at all leave it under-stimulated and let bile stagnate. Regular, balanced meals help keep the gallbladder emptying instead of pooling bile.^[5]
• Discuss your risk and any symptoms with your prescriber. If you have prior gallstones or known risk factors, raise it before or early in treatment. Report upper-abdominal pain, especially after fatty meals, promptly so it can be evaluated rather than dismissed as ordinary GI upset.^[1]
• Ask whether slower dose escalation is appropriate. Because higher doses and faster, larger weight loss carry more gallbladder risk, your prescriber may keep you at a lower dose longer; slower titration is allowed and may improve overall tolerability.^[2]
• Understand the treatment if stones become symptomatic. Many gallstones never cause trouble and need no treatment, but symptomatic stones or cholecystitis are commonly treated with surgical removal of the gallbladder (cholecystectomy). In selected patients undergoing rapid weight loss, some clinicians consider ursodeoxycholic acid to reduce stone formation — but that is a clinician decision for the right candidate, not a routine self-started supplement.^[4]

For dosing, indications, and how tirzepatide is prescribed and monitored, see the Mounjaro drug page; for the closely related upper-abdominal warning condition, see Mounjaro and pancreatitis. A legitimate prescriber screens for gallbladder risk, titrates sensibly, and follows up on abdominal symptoms — exactly the monitoring that keeps this manageable.

Do gallbladder problems go away if I stop Mounjaro?

It depends on what has already happened. The drug-driven slowing of gallbladder emptying is a function of being on the medication, so the ongoing effect eases when the drug is stopped — but gallstones that have already formed do not dissolve on their own just because you stop the drug. Once stones exist, they may stay silent, or they may eventually cause symptoms that need evaluation and possibly removal of the gallbladder.^[3] The weight-loss contribution is also front-loaded: gallstone risk is highest during the period of active, rapid weight loss and tends to settle once weight stabilizes.^[4]

What is never the right move is to stop Mounjaro on your own because of abdominal pain. Sudden, severe upper-right or mid-upper abdominal pain — particularly with fever, vomiting, or jaundice — needs prompt evaluation, not a wait-and-see at home, because it can signal acute cholecystitis or a blocked bile duct (and severe persistent pain can also signal pancreatitis). Bring any gallbladder symptoms to your prescriber, who can decide on imaging, treatment, and whether your weight-loss plan needs adjusting. For how tirzepatide compares with the GLP-1-only agents on this risk, see our companion guide on gallbladder problems on semaglutide.